

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* NEW ENTERPRISE ASSOCIATES 13 LP			2. Issuer Name and Ticker or Trading Symbol Sagimet Biosciences Inc. [SGMT]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/18/2023			4. If Amendment, Date of Original Filed (Month/Day/Year)		
1954 GREENSPRING DRIVE SUITE 600			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person			Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
(Street)	(City)	(State)	(Zip)					
TIMONIUM	MD	21093						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/18/2023		J ⁽¹⁾		37,676	D	(1)	0	D ⁽²⁾	
Series A Common Stock	07/18/2023		J ⁽¹⁾		37,676	A	(1)	37,676	D ⁽²⁾	
Series A Common Stock	07/18/2023		C ⁽³⁾		3,769,857	A	(3)	3,807,533	D ⁽²⁾	
Series A Common Stock	07/18/2023		X		13,404	A	\$0.7948 ⁽⁴⁾	3,820,937	D ⁽²⁾	
Series A Common Stock	07/18/2023		S ⁽⁴⁾		662	D	\$16 ⁽⁴⁾	3,820,275	D ⁽²⁾	
Series A Common Stock	07/18/2023		P		30,000 ⁽⁵⁾	A	\$16	3,850,275	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(3)	07/18/2023		C ⁽³⁾		1,301,130	(3)	(3)	Common Stock	16,370	\$0.00	0	D ⁽²⁾	
Series B-1 Preferred Stock	(3)	07/18/2023		C ⁽³⁾		11,363,635	(3)	(3)	Common Stock	142,974 ⁽⁶⁾	\$0.00	0	D ⁽²⁾	
Series C Preferred Stock	(3)	07/18/2023		C ⁽³⁾		11,363,634	(3)	(3)	Common Stock	142,976	\$0.00	0	D ⁽²⁾	
Series D Preferred Stock	(3)	07/18/2023		C ⁽³⁾		14,659,091	(3)	(3)	Common Stock	184,440	\$0.00	0	D ⁽²⁾	
Series E Preferred Stock	(3)	07/18/2023		C ⁽³⁾		237,893,958	(3)	(3)	Common Stock	2,993,189 ⁽⁶⁾	\$0.00	0	D ⁽²⁾	
Series F Preferred Stock	(3)	07/18/2023		C ⁽³⁾		23,041,474	(3)	(3)	Common Stock	289,908 ⁽⁶⁾	\$0.00	0	D ⁽²⁾	
Common Stock Warrant (right to buy)	\$0.7948	07/18/2023		X		13,404	(4)	01/23/2024	Common Stock	13,404	\$0.00	0	D ⁽²⁾	

1. Name and Address of Reporting Person* NEW ENTERPRISE ASSOCIATES 13 LP		
(Last)	(First)	(Middle)
1954 GREENSPRING DRIVE SUITE 600		
(Street)	(City)	(State)
TIMONIUM	MD	21093
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*
--

BASKETT FOREST

(Last) (First) (Middle)
 1954 GREENSPRING DRIVE
 SUITE 600

(Street)
 TIMONIUM MD 21093

(City) (State) (Zip)

1. Name and Address of Reporting Person*

KERINS PATRICK J

(Last) (First) (Middle)
 1954 GREENSPRING DRIVE
 SUITE 600

(Street)
 TIMONIUM MD 21093

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SANDELL SCOTT D

(Last) (First) (Middle)
 1954 GREENSPRING DRIVE
 SUITE 600

(Street)
 TIMONIUM MD 21093

(City) (State) (Zip)

1. Name and Address of Reporting Person*

NEA Partners 13, Limited Partnership

(Last) (First) (Middle)
 1954 GREENSPRING DRIVE
 SUITE 600

(Street)
 TIMONIUM MD 21093

(City) (State) (Zip)

1. Name and Address of Reporting Person*

NEA 13 GP, Ltd

(Last) (First) (Middle)
 1954 GREENSPRING DRIVE
 SUITE 600

(Street)
 TIMONIUM MD 21093

(City) (State) (Zip)

Explanation of Responses:

- Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was reclassified into one share of Series A Common Stock.
- The securities are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors"), together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Indirect Reporting Persons have no pecuniary interest.
- Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into Series A Common Stock. The Preferred Stock had no expiration date.
- The Common Stock Warrants automatically exercised in connection with the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 662 of the warrant shares to pay the exercise price and issuing to NEA 13 the remaining 12,742 shares, after deducting the aggregate exercise price.
- NEA 13 purchased 30,000 shares of Series A Common Stock of the Issuer in connection with the Issuer's initial public offering.
- The Reporting Persons' Form 3 overreported the number of shares underlying the Preferred Stock by an aggregate of 6 shares.

Remarks:

/s/ Louis Citron, attorney-in-fact 07/20/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.